SignPath gets the go ahead on its curcumin IND

|By:, SA News Editor

The FDA approves SignPath's (SGTH) IND for curcumin, 99.2% pure synthesized diferuloylmethane as a potential treatment for cancer.

The company plans to initiate a Phase 1 trial in 20 - 24 patients with refractory metastatic or recurrent non-small cell lung cancer. Subjects will receive ascending IV doses of Lipocurc (curcumin) once per week for eight weeks to determine the optimal safe dosage.

In another Phase 1 trial, 9 - 12 patients with progressive Parkinson's disease will receive ascending doses of Lipcurc to determine the optimal safe dosage.